Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 15;62(4):505–519. doi: 10.1002/jcph.1980

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Pfizer Inc. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

graphic file with name JCPH-62-505-g004.jpg — Mean (± standard deviation) plasma concentration‐time profiles for abrocitinib (A), PF‐06471658 (M1) (B), PF‐07055087 (M2) (C), and PF‐07054874 (M4) (D) in subjects with normal renal function, moderate renal impairment, or severe renal impairment following a single 200‐mg oral dose of abrocitinib (semilog scale).

graphic file with name JCPH-62-505-g002.jpg — Mean (± standard deviation) plasma concentration‐time profiles for abrocitinib (A), PF‐06471658 (M1) (B), PF‐07055087 (M2) (C), and PF‐07054874 (M4) (D) in subjects with normal renal function, moderate renal impairment, or severe renal impairment following a single 200‐mg oral dose of abrocitinib (semilog scale).